Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Varisacumab - Affitech Research/International Biotech Center Generium/OncXerna Therapeutics

Next Previous
Drug Profile

Varisacumab - Affitech Research/International Biotech Center Generium/OncXerna Therapeutics

Alternative Names: Anti-VEGF antibody AT001/r84; Apagin; AT-001 - IBCG; AT001/r84; Bevacizumab biosimilar - International Biotech Center Generium; Fully humanised monoclonal antibody to VEGF; GNR-011; R-84

Latest Information Update: 02 Apr 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Peregrine Pharmaceuticals; University of Texas Southwestern Medical Center
  • Developer Affitech Research AS
  • Class Antibodies; Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Breast cancer; Colorectal cancer; Eye disorders; Glioblastoma; Non-small cell lung cancer

Most Recent Events

  • 27 Sep 2021 Discontinued - Phase-II/III for Breast cancer in Russia (IV)
  • 27 Sep 2021 Discontinued - Phase-II/III for Colorectal cancer in Russia (IV)
  • 27 Sep 2021 Discontinued - Phase-II/III for Eye disorders in Russia (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top